Such defects could include early responses involving innate, heterotypic, or “pre-existing” virus-specific CD4+ cells, which appear to protect humans from severe influenza in the absence of detectable pathogen-specific antibodies [29], possibly by activating the recently recognized cytotoxic potential of CD4+ cells acting on MHC II-expressing epithelial cells [30]. The gene discussed is CD4; the disease is influenza.